PSA Screening – Medxy AI

Low Baseline PSA Predicts Exceptional Long-Term Safety: A 20-Year Paradigm Shift in Prostate Cancer Screening

By MedXY 02/09/2026

A 20-year cohort study shows that baseline PSA levels in men aged 45-70 are highly predictive of long-term prostate cancer risk, with PSA <1.0 ng/mL indicating a very low 20-year incidence of 3.3%, supporting extended screening intervals for low-risk individuals.

Clinical Updates news Oncology Urology

Stockholm3 Versus PSA in Prostate Cancer Screening: A Synthesis of 9-year Outcomes, Repeat Screening, and Multiethnic Validation

By MedXY 01/09/2026

This review synthesizes long-term outcomes and multiethnic data demonstrating that the Stockholm3 test significantly improves the detection of aggressive prostate cancer while reducing overdiagnosis and unnecessary procedures compared to traditional PSA-based screening.

news Oncology Urology

European Prostate Cancer Screening After 23 Years: Sustained Mortality Reduction and Improved Harm-Benefit Profile

By MedXY 10/31/2025

The 23-year follow-up of the ERSPC confirms that PSA screening reduces prostate cancer mortality by 13%, with an improved harm-benefit ratio, supporting risk-based screening strategies to optimize outcomes.